Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Over Expression of Circulating Mir-155 Predicts Prognosis in Diffuse Large B-Cell Lymphoma Publisher Pubmed



Ahmadvand M1, 2, 3 ; Eskandari M4 ; Pashaiefar H1 ; Yaghmaie M1 ; Manoochehrabadi S5 ; Khakpour G6 ; Sheikhsaran F1 ; Montazer Zohour M7
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hematology-Oncology and Stem Cell Transplantation Research Center, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Cell Therapy and Hematopoietic Stem Cell Transplantation Research Center, Tehran, Iran
  3. 3. Hematologic Malignancies Research Center, Tehran University of Medical Sciences, Tehran, Iran
  4. 4. Pharmaceutical Sciences Branch, Islamic Azad University, Tehran, Iran
  5. 5. Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  6. 6. Department of Medical Genetics and Molecular Biology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
  7. 7. Genetics of Non-Communicable Disease Research Center, Zahedan University of Medical Sciences, Zahedan, Iran

Source: Leukemia Research Published:2018


Abstract

Introduction: The expression patterns of microRNAs in plasma are involved in potential biomarkers for several diseases. The goal of this study was to explore the expression level of miR-155 in diffuse large B-cell lymphoma (DLBCL) and its clinical significance. Materials and methods: We used qRT-PCR to assess the peripheral blood plasma of 40 DLBCL patients for the expression of miRNA-155. The median of miR-155 expression divided the DLBCL patients into miR-155 low-expression (miR-155 low ) and miR-155 high-expression (miR-155 high ) groups. Results and discussion: We found that plasma miR-155 expression was significantly up-regulated in patients with DLBCL (median expression value: 4.29, range: 1.52–27.86) compared to healthy individuals (median expression value: 2.14, range: 0.29–10.56, P < 0.002). Moreover, DLBCL cases with an elevated level of miR-155 had shorter overall survival (median 9 vs. 13 months, P = 0.043) than those with a lower miR-155 expression. © 2018 Elsevier Ltd